Molecular Correlates of Aggressive Behavior and Biological Progression in Testicular Sertoli Cell Tumors

Mod Pathol. 2023 Jul;36(7):100152. doi: 10.1016/j.modpat.2023.100152. Epub 2023 Mar 10.

Abstract

Sertoli cell tumor (SCT) is the second most common type of sex cord-stromal tumor in men, and ∼10% exhibit malignant behavior. Although CTNNB1 variants have been described in SCTs, only a limited number of metastatic cases have been analyzed, and the molecular alterations associated with aggressive behavior remain largely unexplored. This study evaluated a series of nonmetastasizing and metastasizing SCTs using next-generation DNA sequencing to further characterize their genomic landscape. Twenty-two tumors from 21 patients were analyzed. Cases were divided into metastasizing SCTs and nonmetastasizing SCTs. Nonmetastasizing tumors were considered to have aggressive histopathologic features if they exhibited ≥1 of the following: size >2.4 cm, necrosis, lymphovascular invasion, ≥3 mitoses per 10 high-power fields, severe nuclear atypia, or invasive growth. Six patients had metastasizing SCTs, and the remaining 15 patients had nonmetastasizing SCTs; 5 nonmetastasizing tumors had ≥1 aggressive histopathologic feature(s). Gain-of-function CTNNB1 or inactivating APC variants were highly recurrent in nonmetastasizing SCTs (combined frequency >90%), with arm-level/chromosome-level copy number variants, loss of 1p, and CTNNB1 loss of heterozygosity occurring exclusively in CTNNB1-mutant tumors with aggressive histopathologic features or size >1.5 cm. Nonmetastasizing SCTs were almost invariably driven by WNT pathway activation. In contrast, only 50% of metastasizing SCTs harbored gain-of-function CTNNB1 variants. The remaining 50% of metastasizing SCTs were CTNNB1-wild-type and harbored alterations in the TP53, MDM2, CDKN2A/CDKN2B, and TERT pathways. These findings suggest that ∼50% of aggressive SCTs represent progression of CTNNB1-mutant benign SCTs, whereas the remaining ones are CTNNB1-wild-type neoplasms that exhibit alterations in genes of the TP53, cell cycle regulation, and telomere maintenance pathways.

Keywords: Sertoli cell tumor; non–germ cell tumor; sex cord-stromal tumor; testicular cancer; testis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Genomics
  • Humans
  • Male
  • Mitosis
  • Sertoli Cell Tumor* / genetics
  • Sertoli Cell Tumor* / metabolism
  • Sertoli Cell Tumor* / pathology
  • Sex Cord-Gonadal Stromal Tumors* / genetics
  • Sex Cord-Gonadal Stromal Tumors* / pathology
  • Testicular Neoplasms* / pathology